Furthermore, EIF2AK3/PERK signalling has been found to alleviate beta-amyloid associated neurotoxicity [52] and reduce brainstem motor neurone death in a murine model of sleep apnea [53], suggesting that EIF2AK3/PERK pathway activation could be a potential target for therapeutic fields other than cancer, including conditions of hypoxia-associated neurotoxicity and neurodegenerative disorders such as Alzheimers disease. Here, EIF2AK3 is linked to Sleep apnea.